Real-world data often bridges the gap between clinical trials and routine clinical practice. The FLOURISH study provides significant insights into the use of First-line osimertinib in NSCLC within the Chinese population. This prospective trial enrolled 481 treatment-naïve adults with advanced EGFR-mutated disease. Notably, the median time to treatment discontinuation (mTTD) reached 24.6 months. This outcome demonstrates the robust effectiveness of the drug in a broader patient demographic than typically included in pivotal trials.

Real-World Efficacy of First-line Osimertinib in NSCLC

The study results highlighted impressive survival and progression metrics. For instance, the median real-world progression-free survival (rwPFS) was 19.4 months. Furthermore, the overall survival (OS) reached a median of 41.0 months. These figures align closely with previous trial data, suggesting consistent benefits across different settings. Additionally, patients who met the FLAURA eligibility criteria showed an extended OS of 43.1 months. Even those who did not meet these criteria achieved a respectable 33.5 months, confirming the drug's utility in diverse populations.

Prognostic Significance of Genetic Co-mutations

A critical finding of the FLOURISH study involves the negative impact of co-mutations. Patients harboring additional genetic alterations faced significantly diminished clinical benefits. Specifically, the median OS for the co-mutation cohort was only 29.3 months. Conversely, the cohort with EGFR-only mutations had not yet reached its median OS. Consequently, these results suggest that clinicians might need to consider intensified treatment strategies for patients with high-risk genetic profiles.

Safety Profile and Patient Tolerability

Safety remains a paramount concern in long-term cancer therapy. In this study, adverse events occurred in 71.7% of patients. However, most events were manageable, with only 11.4% experiencing grade 3 or higher toxicities. Importantly, safety profiles remained similar between FLAURA-eligible and ineligible patients. Thus, osimertinib continues to show a well-tolerated profile in real-world clinical environments.

Frequently Asked Questions

What was the primary endpoint of the FLOURISH study?

The primary endpoint was the time to treatment discontinuation (TTD). It reached a median of 24.6 months in the study population.

How do co-mutations affect the effectiveness of first-line osimertinib?

The study found that patients with co-mutations had a significantly shorter median overall survival (29.3 months) compared to those with EGFR-only mutations.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Shen L et al. Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer Biol Med. 2026 May 21. doi: undefined. PMID: 42170792.

Myall NJ, et al. Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer. Lung Cancer. 2025 Oct; 108747. doi: 10.1016/j.lungcan.2025.108747. PMID: 40957338.

Lorenzi M et al. Frontline Osimertinib Showcases Real-World Safety, Efficacy in EGFR+ Advanced NSCLC. Presented at: 2021 European Lung Cancer Congress; March 25-27, 2021. Poster 115P.